Unveiling 14 Analyst Insights On Walgreens Boots Alliance
Analysts' ratings for Walgreens Boots Alliance (NASDAQ:WBA) over the last quarter vary from bullish to bearish, as provided by 14 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 1 | 6 | 6 | 0 |
| Last 30D | 0 | 0 | 0 | 1 | 0 |
| 1M Ago | 1 | 1 | 5 | 4 | 0 |
| 2M Ago | 0 | 0 | 1 | 1 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated Walgreens Boots Alliance and provided 12-month price targets. The average target is $13.86, accompanied by a high estimate of $22.00 and a low estimate of $7.00. A decline of 30.46% from the prior average price target is evident in the current average.
Diving into Analyst Ratings: An In-Depth Exploration
The standing of Walgreens Boots Alliance among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Steve Valiquette | Barclays | Lowers | Underweight | $7.00 | $11.00 |
| Kevin Caliendo | UBS | Lowers | Neutral | $12.00 | $17.00 |
| Ben Hendrix | RBC Capital | Lowers | Sector Perform | $13.00 | $22.00 |
| Lisa Gill | JP Morgan | Lowers | Overweight | $20.00 | $30.00 |
| Charles Ryhee | TD Cowen | Lowers | Buy | $22.00 | $35.00 |
| Steve Valiquette | Barclays | Lowers | Underweight | $11.00 | $15.00 |
| David Macdonald | Truist Securities | Lowers | Hold | $13.00 | $20.00 |
| Erin Wright | Morgan Stanley | Lowers | Underweight | $9.00 | $13.00 |
| Allen Lutz | B of A Securities | Lowers | Underperform | $11.00 | $22.00 |
| Elizabeth Anderson | Evercore ISI Group | Lowers | In-Line | $10.00 | $17.00 |
| Kevin Caliendo | UBS | Lowers | Neutral | $17.00 | $22.00 |
| Steve Valiquette | Barclays | Lowers | Underweight | $19.00 | $21.00 |
| Elizabeth Anderson | Evercore ISI Group | Lowers | In-Line | $17.00 | $18.00 |
| Erin Wright | Morgan Stanley | Lowers | Underweight | $13.00 | $16.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Walgreens Boots Alliance. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Walgreens Boots Alliance compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Walgreens Boots Alliance's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Walgreens Boots Alliance's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Walgreens Boots Alliance analyst ratings.
Unveiling the Story Behind Walgreens Boots Alliance
Walgreens Boots Alliance is one of the largest retail pharmacy chains in the US, with over 8,500 locations. Nearly three quarters of Americans live within five miles of a Walgreens location. Roughly two thirds of revenue is generated from prescription drug sales; Walgreens makes up 20% of total prescription revenue in the US. Walgreens also generates sales from retail products (general wellness consumables and its own branded merchandise), European drug wholesale, and healthcare. With more locations incorporating additional services like Health Corner and Village Medical, Walgreens creates an omnichannel experience for patients and positions itself as a one-stop healthcare provider.
Walgreens Boots Alliance: Delving into Financials
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Walgreens Boots Alliance's revenue growth over a period of 3 months has been noteworthy. As of 31 May, 2024, the company achieved a revenue growth rate of approximately 2.64%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 0.95%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Walgreens Boots Alliance's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.54%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Walgreens Boots Alliance's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.41%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 2.4, Walgreens Boots Alliance faces challenges in effectively managing its debt levels, indicating potential financial strain.
What Are Analyst Ratings?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.